Skip to main content
SpringerLink
Log in

Pegfilgrastim — designing an improved form of rmetHuG-CSF

  • Chapter
PEGylated Protein Drugs: Basic Science and Clinical Applications

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

rmetHuG-CSF is the recombinant version of natural granulocyte colony-stimulating factor, the dominant stimulator in the production of neutrophilic leukocytes (neutrophils). Neutrophils represent the first line of defense against invading pathogens and when neutrophil numbers are suppressed by cancer chemotherapy, patients become liable to life-threatening infections.

The clearance of rmetHuG-CSF is effected by a combination of neutrophil mediated degradation and renal filtration. Site-directed addition of a single, linear PEG molecule yielded a form of G-CSF (pegfilgrastim) that was shown to be resistant to renal elimination yet remained sensitive to neutrophilmediated destruction. This semi-synthetic cytokine drug can persist in the plasma for extended periods in neutropenic conditions, yet is cleared rapidly when neutrophils recover. This lends a degree of automation to the therapeutic control of neutrophil numbers which has been exploited in clinical practice since its approval for human use in 2002.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nicola NA, Begley CG, Metcalf D (1985) Identification of the human analog of a regulator that induces differentiation in murine leukemic cells. Nature 314: 625–628

    Article  PubMed  CAS  Google Scholar 

  2. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232: 61–65

    Article  PubMed  CAS  Google Scholar 

  3. Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H (1986) Molecular cloning and expression of cDNA for human granulocyte colonystimulating factor. Nature 319: 415–418

    Article  PubMed  CAS  Google Scholar 

  4. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. British Journal of Cancer 56: 809–813

    PubMed  CAS  Google Scholar 

  5. Gabrilove JL, Jakubowski A, Fain K, Grous J, Scher H, Sternberg C, Yagoda A, Clarkson B, Bonilla MA, Oettgen HF (1988) Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. Journal of Clinical Investigation 82: 1454–1461

    Article  PubMed  CAS  Google Scholar 

  6. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New England Journal of Medicine 318: 1414–1422

    Article  PubMed  CAS  Google Scholar 

  7. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R (1988) Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1: 667–672

    Article  PubMed  CAS  Google Scholar 

  8. Ono M (1994) Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). European Journal of Cancer 30A: Suppl-111

    Google Scholar 

  9. Uzumaki H, Okabe T, Sasaki N, Hagiwara K, Takaku F, Tobita M, Yasukawa K, Ito S, Umezawa Y (1989) Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proceedings of the National Academy of Sciences of the United States of America 86: 9323–9326

    Article  PubMed  CAS  Google Scholar 

  10. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM (1990) Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 76: 2153–2158

    PubMed  CAS  Google Scholar 

  11. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim G-CSF on platelet recovery after high-dose chemotherapy. Lancet 339: 640–644

    Article  PubMed  CAS  Google Scholar 

  12. Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. Journal of Clinical Oncology 7: 1554–1562

    PubMed  CAS  Google Scholar 

  13. Di Leo A, Bajetta E, Nole F, Biganzoli L, Ferrari L, Oriana S, Riboldi G, Bohm S, Spatti G, Raspagliesi F (1994) The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. British Journal of Cancer 69: 961–966

    PubMed  Google Scholar 

  14. Tanaka H, Tokiwa T (1990) Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay. Journal of Pharmacology & Experimental Therapeutics 255: 724–729

    CAS  Google Scholar 

  15. Tanaka H, Kaneko T (1992) Pharmacokinetic and pharmacodynamic comparisons between human granulocyte colony-stimulating factor purified from human bladder carcinoma cell line 5637 culture medium and recombinant human granulocyte colony-stimulating factor produced in Escherichia coli. Journal of Pharmacology & Experimental Therapeutics 262: 439–444

    CAS  Google Scholar 

  16. Eliason JF, Greway A, Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, Horii I (2000) Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells (Miamisburg) 18: 40–45

    Article  CAS  Google Scholar 

  17. Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE (1993) Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. Journal of Pediatrics 123: 471–479

    Article  PubMed  CAS  Google Scholar 

  18. Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J (1995) Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. Journal of Clinical Investigation 95: 2973–2978

    Article  PubMed  CAS  Google Scholar 

  19. Marsh JC, Gibson FM, Prue RL, Bowen A, Dunn VT, Hornkohl AC, Nichol JL, Gordon-S mith EC (1996) Serum thrombopoietin levels in patients with aplastic anaemia. British Journal of Haematology 95: 605–610

    Article  PubMed  CAS  Google Scholar 

  20. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR (1996) Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87: 4068–4071

    PubMed  CAS  Google Scholar 

  21. Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller GA, de Sauvage FJ, Eaton D (1997) Human platelets as a model for the binding and degradation of thrombopoietin. Blood 89: 2782–2788

    PubMed  CAS  Google Scholar 

  22. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y (1997) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology & Experimental Therapeutics 283: 520–527

    CAS  Google Scholar 

  23. Redman BG, Flaherty L, Chou TH, Kraut M, Martino S, Simon M, Valdivieso M, Groves E (1992) Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. Journal of Immunotherapy 12: 50–54

    Article  PubMed  CAS  Google Scholar 

  24. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD (1994) Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. Journal of Pharmacology & Experimental Therapeutics 268: 152–158

    CAS  Google Scholar 

  25. Layton JE, Hockman H, Sheridan WP, Morstyn G (1989) Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 74: 1303–1307

    PubMed  CAS  Google Scholar 

  26. Shimazaki C, Uchiyama H, Fujita N, Araki S, Sudo Y, Yamagata N, Ashihara E, Goto H, Inaba T, Haruyama H (1995) Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Experimental Hematology 23: 1497–1502

    PubMed  CAS  Google Scholar 

  27. Takatani H, Soda H, Fukuda M, Watanabe M, Kinoshita A, Nakamura T, Oka M (1996) Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrobial Agents & Chemotherapy 40: 988–991

    CAS  Google Scholar 

  28. Stute N, Santana VM, Rodman J H, Schell MJ, Ihle JN, Evans WE (1992) Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79: 2849–2854

    PubMed  CAS  Google Scholar 

  29. Sturgill MG, Huhn RD, Drachtman RA, Ettinger AG, Ettinger LJ (1997) Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neu-trophil count with repeated dosing. American Journal of Hematology 54: 124–130

    Article  PubMed  CAS  Google Scholar 

  30. Briddell R, Stonev G, Molineux G (2001) Investigation of the mode of clearance of filgrastim and filgrastim SD/01 by human peripheral blood neutrophils in vitro. Experimental Hematology 29

    Google Scholar 

  31. Tanaka H, Tokiwa T (1990) Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor krn-8601 in the rat. Cancer Research 50:6615–6619

    PubMed  CAS  Google Scholar 

  32. Kuwabara T, Ishikawa Y, Kobayashi H, Kobayashi S, Sugiyama Y (1995) Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharmaceutical Research 12: 1466–1469

    Article  PubMed  CAS  Google Scholar 

  33. Tanaka J, Miyake T, Shimizu T, Wakayama T, Tsumori M, Koshimura K, Murakami Y, Kato Y (2002) Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: A feasibility study. International Journal of Hematology 75: 489–492

    Article  PubMed  CAS  Google Scholar 

  34. Furuya H, Wakayama T, Ohguni S, Yamauchi K, Tanaka J, Hatazoe T, Kato Y (1995) Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin’s lymphoma receiving chemotherapy. International Journal of Hematology 61: 123–129

    Article  PubMed  CAS  Google Scholar 

  35. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer serum half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematology 31: 290–299

    Article  PubMed  CAS  Google Scholar 

  36. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I (2004) Control of rHuEPO biological activity: The role of carbohydrate. Experimental Hematology 32: 1146–1155

    Article  PubMed  CAS  Google Scholar 

  37. Heatherington AC, Schuller J, Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. British Journal of Cancer 84: Suppl-6

    Google Scholar 

  38. Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu M-L, Hirsch J, Mahoney A, Carrell J, Boyd E et al. (2002) AlbugraninTM, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharmaceutical Research 19: 1720–1729

    Article  PubMed  CAS  Google Scholar 

  39. Jensen-Pippo KE, Whitcomb KL, Deprince RB, Ralph L, Habberfield AD (1996) Enternal bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharmaceutical Research (New York) 13: 102–107

    CAS  Google Scholar 

  40. Choi SH, Lee H, Park TG (2003) PEGylation of G-CSF using cleavable oligo-lactic acid linkage. Journal of Controlled Release 89: 271–284

    Article  PubMed  CAS  Google Scholar 

  41. DeFrees S, Wang Z-G, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden ECM et al. (2006) GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16: 833–843

    Article  PubMed  CAS  Google Scholar 

  42. Mueller H-J, Loening L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schuetz V, Henze G, da Palma JC, Ritter J et al. (2000) Pegylated asparaginase (OncasparTM) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology 110: 379–384

    Article  Google Scholar 

  43. Melton A, Hershfield MS, Greenberg ML, Hatem C, Markert ML, Kurtzberg J, Abuchowski A, Buckley RH (1987) Treatment of adenosine deaminase-deficient severe combined immune deficiency ADA-SCID with polyethylene glycol-modified bovine adenosine deaminase PEG-ADA. Journal of Allergy & Clinical Immunology 79: 252

    Google Scholar 

  44. Karasiewicz R, Nalin C, Rosen P (1995) Peg-interferon conjugates. Official Gazette of the United States Patent & Trademark Office Patents: 17, 1995

    Google Scholar 

  45. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, Ehrlich GK, Pan W, Xu Z-X, Modi MW et al. (2001) Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chemistry 12: 195–202

    Article  PubMed  CAS  Google Scholar 

  46. Malik F, Brew J, Maidment SA, Delgado C, Francis GE (2000) PEG-modified erythropoietin with improved efficacy. Experimental Hematology 28: 106

    Article  Google Scholar 

  47. Sato H, Yamamoto K, Hayashi E, Takahara Y (2000) Transglutaminase-mediated dual and sitespecific incorporation poly(ethylene glycol) derivatives into a chimeric interleukin-2. Bioconjugate Chemistry 11: 502–509

    Article  PubMed  CAS  Google Scholar 

  48. Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T et al. (1995) Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86: 4486–4492

    PubMed  CAS  Google Scholar 

  49. Jolling K, Ruixo JJP, Hemeryck A, Piotrovskij V, Greway T (2004) Population pharmacokinetic analysis of pegylated human erythropoietin in rats. Journal of Pharmaceutical Sciences 93: 3027–3038

    Article  PubMed  CAS  Google Scholar 

  50. Kuan C-T, Wang Q-C, Pastan I (1994) Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. Journal of Biological Chemistry 269: 7610–7616

    PubMed  CAS  Google Scholar 

  51. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proceedings of the National Academy of Sciences of the United States of America 97: 8548–8553

    Article  PubMed  CAS  Google Scholar 

  52. Benhar I, Wang Q-C, Fitzgerald D, Pastan I (1994) Pseudomonas exotoxin A mutants: Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. Journal of Biological Chemistry 269: 13398–13404

    PubMed  CAS  Google Scholar 

  53. Gaertner HF, Offord RE (1996) Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chemistry 7: 38–44

    Article  PubMed  CAS  Google Scholar 

  54. Wang M, Lee LS, Nepomich A, Yang J-D, Conover C, Whitlow M, Filpula D (1 277) Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Engineering 11:1277–1283

    Google Scholar 

  55. Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ (1996) Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceutical Research 13: 996–1002

    Article  PubMed  CAS  Google Scholar 

  56. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C (2002) Mono-N-terminal polyethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews 54(4): 477–485

    Article  PubMed  CAS  Google Scholar 

  57. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA et al. (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Experimental Hematology 27: 1724–1734

    Article  PubMed  CAS  Google Scholar 

  58. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang B-B, Gardner S, Miller-Messana MA, Shoemaker D et al. (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology 18:2522–2528

    PubMed  CAS  Google Scholar 

  59. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR et al. (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 14: 29–35

    Article  PubMed  CAS  Google Scholar 

  60. Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I et al. (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology 20: 727–731

    Article  PubMed  CAS  Google Scholar 

  61. Yang B-B, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. Journal of Pharmaceutical Sciences 93: 1367–1373

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Mailstop 15-22A, Thousand Oaks, California, 91320, USA

    Graham Molineux

Authors
  1. Graham Molineux
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, University of Padova, 35131, Padova, Italy

    Francesco M. Veronese

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Molineux, G. (2009). Pegfilgrastim — designing an improved form of rmetHuG-CSF. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_10

Download citation

Publish with us

Policies and ethics

Search

Navigation